4//SEC Filing
Pershing Edward 4
Accession 0001493152-25-019326
CIK 0000315545other
Filed
Oct 23, 8:00 PM ET
Accepted
Oct 24, 4:48 PM ET
Size
6.7 KB
Accession
0001493152-25-019326
Insider Transaction Report
Form 4
Pershing Edward
DirectorCEO
Transactions
- Award
8% Unsecured Convertible Promissory Note
2025-10-23Exercise: $2.86From: 2025-10-23Exp: 2026-10-23→ Series D-1 Convertible Preferred Stock (6,989 underlying)
Footnotes (2)
- [F1]The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2025 Financing.
- [F2]Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.
Documents
Issuer
PROVECTUS BIOPHARMACEUTICALS, INC.
CIK 0000315545
Entity typeother
Related Parties
1- filerCIK 0001689739
Filing Metadata
- Form type
- 4
- Filed
- Oct 23, 8:00 PM ET
- Accepted
- Oct 24, 4:48 PM ET
- Size
- 6.7 KB